Results 31 to 40 of about 38,609 (257)

Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors. [PDF]

, 2023
IMPORTANCE: New dosing options for immune checkpoint inhibitors have recently been approved by the US Food and Drug Administration (FDA), including fixed dosing with extended intervals.
Rosenbaum, E, Chan, KKW, Zer, A, Hall, PS, Loong, HH, Ginsberg, GM, Goh, BC, Perrone, F, De Abreu Lourenco, R, Hofnung-Gabbay, D, Di Maio, M, Goldstein, DA   +11 more
core   +1 more source

Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic. [PDF]

Respir Med Res, 2023
International audienceBackground: The COVID 19-pandemic has led physicians to change their approach to treating non-small cell lung cancer (NSCLC) to reduce hospital stays for patients. Objectives: We aimed to assess the toxicity and efficacy of extended
Veron M, Pierret T, Pérol M, Bettega F, Benet J, Denis N, Moro-Sibilot D, Swalduz A, Toffart AC.   +8 more
europepmc   +2 more sources

COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients. [PDF]

J Neurol, 2023
Introduction During the COVID-19 pandemic, ocrelizumab (OCR) infusions for MS patients were often re-scheduled because of MS center's disruption and concerns regarding immunosuppression.
Bisecco A, Matrone F, Capobianco M, De Luca G, Filippi M, Granella F, Lus G, Marfia GA, Mirabella M, Patti F, Trojano M, Mascolo A, Copetti M, Tedeschi G, Gallo A, OCREVID study group on behalf of the Italian MS Register.   +15 more
europepmc   +6 more sources

Adjusted dose regimens in dupilumab treatment for atopic dermatitis: Daily practice experiences

JEADV Clinical Practice, 2022
Background Clinical trials with dupilumab in atopic dermatitis (AD) patients showed a trend towards better effectiveness with a weekly or biweekly dosing interval, compared with extended dosing intervals.
Jill I. Olydam, Linde E. M. deWijs, Tamar E. C. Nijsten, Joost vanRosmalen, Dirk Jan Hijnen   +4 more
doaj   +1 more source

Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience. [PDF]

Curr Neuropharmacol
: The intervals between two courses of anti CD20 therapies in the COVID19 pandemic era provided the opportunity to individually delay therapy, known as extended interval dosing (EID).
Zanghì A, Ferraro D, Callari G, Valentino P, Granella F, Patti F, Lus G, Bonavita S, Moretti MC, Avolio C, D'Amico E.   +10 more
europepmc   +2 more sources

Extended-interval dosing of rituximab/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosis. [PDF]

Neurotherapeutics
International audienceThe potential benefits of extended-interval dosing (EID) of rituximab (RTX) or ocrelizumab (OCR) in mitigating the reduction of immunoglobulin levels and decreasing the risk of infection in persons with relapsing-remitting multiple ...
Rigollet C, Freeman SA, Perriguey M, Stellmann JP, Graille-Avy L, Lafontaine JC, Lemarchant B, Alberto T, Demortière S, Boutiere C, Rico A, Hilézian F, Durozard P, Pelletier J, Maarouf A, Zéphir H, Audoin B.   +16 more
europepmc   +2 more sources

Flea and tick treatment satisfaction, preference, and adherence of U.S. cat owners prescribed topical fluralaner (Bravecto® Topical Solution for Cats) [PDF]

Open Veterinary Journal, 2021
Background: Fluralaner is a novel isoxazoline compound and the only systemically distributed ectoparasiticide approved in the United States for re-dosing at up to 12-week intervals for flea and tick control in cats.
Robert Lavan, Dorothy Normile, Rob Armstrong, Wendy Vaala   +3 more
doaj   +1 more source

Flea and tick treatment satisfaction, preference, and adherence reported by cat owners in the U.S., U.K., or France who treated their cats with transdermal fluralaner [PDF]

Open Veterinary Journal, 2021
Background: Fluralaner (Bravecto®) is an isoxazoline class compound that is the only topically applied systemic ectoparasiticide approved for dosing at up to 12-week intervals for flea and tick control in cats.
Robert Philip Lavan, Rob Armstrong, Hannah Newbury, Dorothy Normile, Celine Hubinois   +4 more
doaj   +1 more source

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

Therapeutic Advances in Neurological Disorders, 2021
Background: Extended interval dosing of natalizumab is associated with significantly lower progressive multifocal leukoencephalopathy risk compared with every-4-week (Q4W) dosing in patients with relapsing-remitting multiple sclerosis.
Helmut Butzkueven, Ludwig Kappos, Tim Spelman, Maria Trojano, Heinz Wiendl, Ray Su, Shirley Liao, Robert Hyde, Stephanie Licata, Pei-Ran Ho, Nolan Campbell   +10 more
doaj   +1 more source

Extended dosing of monoclonal antibodies in multiple sclerosis

, 2021
Over the past two decades, treatment options for patients with multiple sclerosis (MS) have increased exponentially. In the current therapeutic landscape, “no evidence of MS disease activity” is within reach in many of our patients.
Toorop, Alyssa A., Sellebjerg, Finn, Killestein, Joep, Giovannoni, Gavin, van Kempen, Zoé L.E., van Kempen, Zoé L. E.   +5 more
core   +1 more source